Granger K A, Farquharson R G
Liverpool Women's Hospital, UK.
Lupus. 1997;6(6):509-13. doi: 10.1177/096120339700600606.
The presence of lupus anticoagulant (LA) and anticardiolipin antibodies (ACA) are associated with recurring pregnancy loss. Of 387 consecutive patients investigated at a Recurring Miscarriage Clinic over a three year period, 63 (16%) were positive for LA and ACA or both. Fifty-nine patients by definition were classified as having antiphospholipid syndrome and four also had systemic lupus erythematosus (SLE). Fifty-three subsequent pregnancies occurred in 63 patients and of these 37 ended in a live birth giving an overall livebirth rate of 70%. Treatment included low dose aspirin alone in 37 pregnancies and low dose aspirin and low molecular weight heparin (LMWH) in 16 pregnancies. The decision for treatment was made empirically on past obstetric history and level of LA and ACA, and past history of venous thromboembolic disease. Obstetric outcome was worst in the group who were positive for both LA and ACA, with a success rate of 53%, compared to 72 or 81% in the single parameter groups. Complications in the 37 successful pregnancies included eight Caesarean sections, four cases of intra-uterine growth restriction, one case of pregnancy induced proteinuric hypertension, one deep vein thrombosis and one pulmonary embolism. Patients with antiphospholipid syndrome are at high risk of pregnancy loss as well as maternal morbidity, especially thrombo-embolic disease. A randomised prospective controlled trial is necessary to determine the optimum therapy for pregnancy conservation and thrombprophylaxis.
狼疮抗凝物(LA)和抗心磷脂抗体(ACA)的存在与复发性流产相关。在一家复发性流产诊所三年期间连续调查的387例患者中,63例(16%)LA和ACA呈阳性或两者均阳性。根据定义,59例患者被归类为患有抗磷脂综合征,4例还患有系统性红斑狼疮(SLE)。63例患者随后发生了53次妊娠,其中37次以活产告终,总体活产率为70%。治疗包括37次妊娠单独使用低剂量阿司匹林,16次妊娠使用低剂量阿司匹林和低分子量肝素(LMWH)。治疗决策根据既往产科病史、LA和ACA水平以及既往静脉血栓栓塞性疾病史凭经验做出。LA和ACA均呈阳性的组产科结局最差,成功率为53%,而单参数组的成功率为72%或81%。37例成功妊娠的并发症包括8例剖宫产、4例宫内生长受限、1例妊娠诱发的蛋白尿性高血压、1例深静脉血栓形成和1例肺栓塞。抗磷脂综合征患者发生流产以及孕产妇发病尤其是血栓栓塞性疾病的风险很高。有必要进行一项随机前瞻性对照试验来确定妊娠保护和血栓预防的最佳治疗方法。